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Background
Current chemotherapy of acute myeloid leukaemia
(AML) is limited by systemic toxicity. New agents are
needed with increased selectivity for malignant cells and
reduced toxicity.
Materials and methods
Triplebodies are a new class of antibody derivatives
developed by our team, which consist of 3 antigen-bind-
ing domains carried in a single polypeptide chain. The
distal domains bind 2 targets on the same cancer cell,
the central domain binds a trigger molecule on an effec-
tor cell. If the 2 targets on the cancer cell are different,
the triplebody is said to be ‘dual-targeting’. The key new
capability resulting from dual-targeting is the elimina-
tion of cancer cells with ‘increased selectivity’ (Schubert
2013; MAbs. PMID 24135631).
Here the dual-targeting triplebody 33-16-123 (SPM-2)
was developed and tested in redirected lysis assays
in vitro. It carries binding domains for the surface anti-
gens CD33 and CD123 on AML cells and for CD16, the
Fc gamma RIII receptor on Natural Killer (NK) cells. This
pair of target antigens is expressed on the blasts of a
majority of AML patients and is present in increased sur-
face density on AML-leukaemia stem cells (LSCs) relative
to bulk AML cells and healthy hematopoietic stem cells.
This combination offers the possibility of preferential tar-
geting of AML-LSCs, and thus of minimal residual disease
(MRD) cells.
Human AML cell-lines and primary cells freshly drawn
from AML patients were used in redirected lysis experi-
ments. Target cells were labeled with Calcein AM. Effector
cells were either ex vivo expanded mononuclear cells from
healthy donors, or patient’s autologous NK cells enriched
by immunomagnetic beads. Reactions proceeded for 4 hrs,
and specific lysis was measured by release of fluorescent
Calcein using an ELISA plate reader. Multicolor cyto-
fluorimetry with fluorescent-labeled antibodies was used
in addition to study elimination of subsets of AML cells.
Results
SPM-2 effectively eliminated human AML cell lines
including MOLM-13, which are double-positive for CD33
and CD123, with an EC50 concentration in the range of
20-50 pM, as well as primary blasts from AML patients
with various subtypes of AML with EC50 concentrations
in the range of 50-100 pM. Less than 10% of myeloid cells
from healthy donors enriched for CD33-positive cells were
lysed by SPM-2 used in a 10 nM dose. Therefore, a clear
therapeutic window appears to exist. For some patient
samples SPM-2 also produced effective lysis of the
CD34pos and the CD34pos CD38neg CD123pos subsets,
which encompass the MRD cells.
Conclusions
SPM-2 mediated efficient redirected lysis in vitro by NK-
cells, both of established human AML-derived cell lines
and of freshly drawn blasts from patients with various
subtypes of AML. SPM-2 also mediated lysis of cellular
subsets encompassing the AML-LSCs and thus of the
MRD cells responsible for relapsed disease. The agent is
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promising for lysis of AML cells in vivo with increased
selectivity and reduced systemic toxicity and is scheduled
for clinical development.
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